A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
By R. Pisters, D. Lane, R. Nieuwlaat, Cees B de Vos, H. Crijns, Gregory Y. H. Lip. Chest, 2010
4,487 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Neurology
View Paper: https://www.semanticscholar.org/paper/0277f03eb14449c30f7224d82f70663d953b62f6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report (2012, methodology): “Following age and prior bleeding, the most prevalent bleeding risk factors included in the scores are anemia,(69,99-102) renal disease,(69,98,99,101) hypertension(69,102) or uncontrolled systolic BP,(98) concomitant antiplatelets,(98,101,102) and alcohol excess,(98,99,102) and prior stroke(98,99) or”
- Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). (2011, methodology): “51,52 With release of initial results from the SHARP (Study of Heart and Renal Protection) trial, statins may now be the best-studied medical therapy in the context of advanced CKD.”